miltefosine has been researched along with Breast Neoplasms in 28 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 7.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 6.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 6.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 3.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
| "Miltefosine (hexadecylphosphocholine) is used for topical treatment of breast cancers." | 3.71 | MDR1 causes resistance to the antitumour drug miltefosine. ( Grunicke, H; Hofmann, J; Liu, R; Lu, P; Pietro, AD; Rybczynska, M; Sharom, FJ; Spitaler, M; Steinfels, E, 2001) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 2.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 2.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "D-19391 was added to the SK-BR-3 breast cancer cell line and HePC to the Molt-4 leukemia cell line in concentrations of, respectively, 18." | 1.30 | Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. ( Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D, 1999) |
| " Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data." | 1.30 | Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999) |
| "Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
| "Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | 1.28 | Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
| " After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 19 (67.86) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Jangir, S | 1 |
| Bala, V | 1 |
| Lal, N | 1 |
| Kumar, L | 1 |
| Sarswat, A | 1 |
| Kumar, A | 1 |
| Saini, KS | 1 |
| Sharma, V | 1 |
| Verma, V | 1 |
| Maikhuri, JP | 1 |
| Konwar, R | 1 |
| Gupta, G | 1 |
| Sharma, VL | 1 |
| El-Sheridy, NA | 1 |
| El-Moslemany, RM | 1 |
| Ramadan, AA | 1 |
| Helmy, MW | 1 |
| El-Khordagui, LK | 1 |
| Chakrabandhu, K | 1 |
| Huault, S | 1 |
| Hueber, AO | 1 |
| Lopez Lopez, R | 1 |
| van Rijswijk, RE | 1 |
| Wagstaff, J | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Fichtner, I | 5 |
| Zeisig, R | 4 |
| Naundorf, H | 2 |
| Jungmann, S | 1 |
| Arndt, D | 4 |
| Asongwe, G | 1 |
| Double, JA | 1 |
| Bibby, MC | 2 |
| Bruyneel, EA | 1 |
| Storme, GA | 1 |
| Schallier, DC | 1 |
| Van den Berge, DL | 1 |
| Hilgard, P | 5 |
| Mareel, MM | 1 |
| Colombo, DT | 2 |
| Tran, LK | 2 |
| Reitz, RC | 2 |
| Clive, S | 2 |
| Leonard, RC | 2 |
| Eue, I | 1 |
| Sternberg, B | 1 |
| Safa, O | 1 |
| Parkin, SM | 1 |
| Speck, JJ | 1 |
| Stahn, R | 1 |
| Terwogt, JM | 1 |
| Mandjes, IA | 1 |
| Sindermann, H | 5 |
| Beijnen, JH | 1 |
| ten Bokkel Huinink, WW | 1 |
| Brochez, V | 1 |
| Van Heuverswyn, D | 1 |
| Diniz, JA | 1 |
| De Potter, CR | 1 |
| Van den Eeckhout, EG | 1 |
| Gardiner, J | 1 |
| Teppke, AD | 1 |
| Fahr, A | 1 |
| Smorenburg, CH | 1 |
| Seynaeve, C | 1 |
| Bontenbal, M | 1 |
| Planting, AS | 1 |
| Verweij, J | 1 |
| Moĭseenko, VM | 1 |
| Orlova, RV | 1 |
| Ermakova, NA | 1 |
| Protsenko, SA | 1 |
| Rybczynska, M | 1 |
| Liu, R | 1 |
| Lu, P | 1 |
| Sharom, FJ | 1 |
| Steinfels, E | 1 |
| Pietro, AD | 1 |
| Spitaler, M | 1 |
| Grunicke, H | 1 |
| Hofmann, J | 1 |
| Leonard, R | 1 |
| Hardy, J | 1 |
| van Tienhoven, G | 1 |
| Houston, S | 1 |
| Simmonds, P | 1 |
| David, M | 1 |
| Mansi, J | 1 |
| Haberkorn, U | 1 |
| Reinhardt, M | 2 |
| Strauss, LG | 1 |
| Oberdorfer, F | 1 |
| Berger, MR | 2 |
| Altmann, A | 1 |
| Wallich, R | 1 |
| Dimitrakopoulou, A | 1 |
| van Kaick, G | 1 |
| Unger, C | 5 |
| Peukert, M | 3 |
| Engel, J | 3 |
| Eibl, H | 5 |
| Rewasowa, EC | 1 |
| Büttner, B | 1 |
| Becker, M | 1 |
| Görlich, M | 1 |
| Yanapirut, P | 1 |
| Schmähl, D | 1 |
| Nagel, G | 2 |
| Damenz, W | 1 |
| Fleer, EA | 1 |
| Kim, DJ | 1 |
| Breiser, A | 2 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for miltefosine and Breast Neoplasms
| Article | Year |
|---|---|
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; | 1990 |
5 trials available for miltefosine and Breast Neoplasms
| Article | Year |
|---|---|
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1999 |
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middl | 2000 |
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin | 2000 |
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Do | 2001 |
22 other studies available for miltefosine and Breast Neoplasms
| Article | Year |
|---|---|
Novel alkylphospholipid-DTC hybrids as promising agents against endocrine related cancers acting via modulation of Akt-pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ditiocarb; Drug Sc | 2014 |
Enhancing the
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutica | 2021 |
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fas Ligand Protein; fas Recept | 2008 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.
Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 1994 |
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Female; Gene Expression Regulation, Neoplast | 1993 |
The effects of hexadecylphosphocholine (HPC) a mixture of alkylphosphocholines (APC) and different dietary oils on the growth of a human mammary tumor.
Topics: Animals; Breast Neoplasms; Corn Oil; Dietary Fats, Unsaturated; Dinoprostone; Fish Oils; Humans; Mic | 1993 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi | 1997 |
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Cholesterol; Ethanol | 1997 |
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Gene Expre | 1997 |
Comparison of hexadecylphosphocholine with fish oil as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dinoprostone; Docosahexaenoic Acids; Drug Combinat | 1997 |
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice, | 1998 |
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; R | 1999 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea | 1999 |
MDR1 causes resistance to the antitumour drug miltefosine.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2001 |
Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatogra | 1992 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; | 1992 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A | 1992 |
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Hum | 1991 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1990 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr | 1988 |